Carcinoma, Transitional CellPhase 1/2EV-103NCT03288545
A Study of Enfortumab Vedotin Alone or With Other Therapies for Treatment of Urothelial Cancer
A Phase 1/2 study testing enfortumab vedotin (EV), pembrolizumab and cisplatin in people with Carcinoma, Transitional Cell and Urinary Bladder Neoplasms, run by Astellas Pharma Global Development, Inc. at 106 sites in 6 countries.
Trial summary
This study will test an experimental drug (enfortumab vedotin) alone and with different combinations of anticancer therapies. Pembrolizumab is an immune checkpoint inhibitor (CPI) that is used to treat patients with cancer of the urinary system (urothelial cancer). Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Carcinoma, Transitional Cell, Urinary Bladder Neoplasms, Urologic Neoplasms
- What is being tested?
- enfortumab vedotin (EV), pembrolizumab and cisplatin
- Type of treatment
- Injection or infusion
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 348 participants
- Where
- 106 sitesin 6 countries
- Study dates
- 11 Oct 2017to 20 Feb 2026
- Phase
- Phase 1/2
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Locally advanced or metastatic urothelial cancer (la/mUC) - Cohorts A, B, D, E, F, G and K.
- Histologically documented la/mUC, including squamous differentiation or mixed cell types.
- An Eastern Cooperative Oncology Group (ECOG) Performance Status score of 0, 1 or 2: Participants with ECOG performance status of 2 must meet the following additional criteria: hemoglobin ≥10 g/dL, GFR ≥50 mL/min, may not have NYHA Class III heart failure.
- Eligible for pembrolizumab (Dose-escalation cohorts, Cohorts A, B, G and K Combination Arm).
- Dose-escalation cohorts: Ineligible for first-line cisplatin-based chemotherapy and no prior treatment for la/mUC, or have disease progression following at least 1 platinum-containing treatment.
- Cohort A: Ineligible for cisplatin-based chemotherapy and no prior treatment for la/mUC. No prior adjuvant/neoadjuvant platinum-based therapy in at least 12 months.
Show all 20Show fewer
- Cohort B: Must have disease progression during/following treatment with at least 1 platinum-containing regimen for la/mUC or disease recurrence.
- Cohort D: Eligible for cisplatin-based chemotherapy and no prior treatment for la/mUC. No prior adjuvant/neoadjuvant platinum-based therapy in at least 12 months.
- Cohort E: Ineligible for cisplatin-based chemotherapy, eligible for carboplatin, and no prior treatment for la/mUC. No prior adjuvant/neoadjuvant platinum-based therapy in at least 12 months.
- Cohort F: Ineligible for platinum-based chemotherapy, or disease progression during/following at least 1 prior treatment for la/mUC. Eligible for gemcitabine.
- Cohort G: Eligible for platinum-based chemotherapy (either cisplatin or carboplatin) and no prior treatment for la/mUC. No prior adjuvant/neoadjuvant platinum-based therapy in at least 12 months.
- Cohort K: Ineligible for cisplatin-based chemotherapy due to at least 1 of the following: Glomerular filtration rate (GFR) <60 mL/min and ≥30 mL/min, ECOG performance status of 2, NCI CTCAE Version 4.03 Grade ≥2 hearing loss, New York Heart Association (NYHA) Class III heart failure. No prior systemic treatment for locally advanced or metastatic disease. No adjuvant/neoadjuvant platinum-based therapy within 12 months prior to randomization.
- Muscle Invasive Bladder Cancer (MIBC)- Cohorts H, J and L.
- Histologically confirmed MIBC with predominant >50% urothelial histology: Cohorts H and J: Clinical stage cT2-T4aN0M0; Cohort L: Clinical stage cT2-T4aN0M0 or cT1-T4aN1M0: Participants with pT1 disease are eligible only if they have N1 disease on imaging. Mixed cell types are eligible if urothelial cancer is predominant (>50%); Participants with plasmacytoid and/or neuroendocrine tumors are ineligible regardless of component percentage. Urothelial tumors not originating in the bladder (eg, upper tract tumors, urethral tumors) are ineligible.
- Must be cisplatin-ineligible.
- Cohort-specific eligibility: Cohort J, H, and L: No prior systemic treatment, chemoradiation, or radiation therapy for MIBC. May have received prior intravesical Bacillus Calmette-Guerin (BCG) or intravesical chemotherapy for non-MIBC; Cohort J: Eligible for pembrolizumab.
- ECOG performance status of 0, 1, or 2.
- Anticipated life expectancy of ≥3 months.
- Tumor samples with an associated pathology report from the diagnostic transurethral resection of a bladder tumor done 90 days prior to the first dose of study treatment must be available prior to enrollment and determined to be sufficient for pathology review and biomarker analysis.
- Participants must be deemed eligible for RC+PLND.
Who cannot join
- la/mUC - Cohorts A, B, D, E, F, G, and K
- Received any prior treatment with a PD-1 inhibitor, PD-L1 inhibitor, or PD-L2 inhibitor, except Cohort F.
- Received any prior treatment with stimulatory or co-inhibitory T-cell receptor agents, such as CD137 agonists, OX-40 agonists, or cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) inhibitors (except Cohort F).
- Ongoing sensory or motor neuropathy Grade 2 or higher.
- Active central nervous system (CNS) metastases.
- Ongoing clinically significant toxicity (Grade 2 or greater) associated with prior treatment (including radiotherapy or surgery).
Show all 19Show fewer
- Conditions requiring high doses of steroids or other immunosuppressive medications.
- Prior treatment with enfortumab vedotin or other monomethyl auristatin E (MMAE)-based antibody-drug conjugates (ADCs).
- Uncontrolled diabetes mellitus.
- MIBC - Cohorts H, J, and L
- Received prior systemic treatment, chemoradiation, and/or radiation therapy of muscle invasive bladder cancer.
- Received any prior treatment with a CPI.
- Received any prior treatment with stimulatory or co-inhibitory T-cell receptor agents, such as CD137 agonists, CTLA-4 inhibitors, or OX-40 agonists.
- For participants in Cohort H, evidence of nodal disease on imaging. For participants in Cohort L, ≥N2 nodal disease on imaging.
- Participant has undergone partial cystectomy of the bladder to remove any NMIBC or MIBC.
- Ongoing sensory or motor neuropathy Grade 2 or higher.
- Conditions requiring high doses of steroids or other immunosuppressive medications.
- Prior treatment with enfortumab vedotin or other MMAE-based ADCs for urothelial cancer.
- Participants with a history of another invasive malignancy within 3 years before first dose of study drug.
Trial locations and contacts
106 sites in 6 countries.
106 sites in 6 countries
United States83 sites
New York Oncology Hematology, P.C.
Albany, New York, 12206
University of New Mexico Cancer Center
Albuquerque, New Mexico, 87106
Alaska Urological Institute
Anchorage, Alaska, 99503
University of Michigan Comprehensive Cancer Center
Ann Arbor, Michigan, 48109
Piedmont Cancer Institute
Atlanta, Georgia, 30309
Winship Cancer Institute / Emory University School of Medicine
Atlanta, Georgia, 30322
Rocky Mountain Cancer Centers - Aurora
Aurora, Colorado, 80012
University of Colorado Hospital / University of Colorado
Aurora, Colorado, 80045-0510
Memorial Sloan Kettering Cancer Center - Basking Ridge
Basking Ridge, New Jersey, 07920
Tower Hematology Oncology Medical Group
Beverly Hills, California, 90211
Boca Raton Regional Hospital / Lynn Cancer Institute
Boca Raton, Florida, 33486
CMOH Broomall
Broomall, Pennsylvania, 19008
Roswell Park Cancer Institute
Buffalo, New York, 14263
Gabrail Cancer Center Research, LLC
Canton, Ohio, 44718
UNC Lineberger Comprehensive Cancer Center / University of North Carolina
Chapel Hill, North Carolina, 27599
Medical University of South Carolina/Hollings Cancer Center
Charleston, South Carolina, 29425
Levine Cancer Institute
Charlotte, North Carolina, 28204
University of Virginia
Charlottesville, Virginia, 22903
Sarah Cannon Research Institute
Chattanooga, Tennessee, 37404
University of Chicago Medical Center
Chicago, Illinois, 60637-1470
Case Western Reserve University / University Hospitals Case Medical Center
Cleveland, Ohio, 44106
Memorial Sloan Kettering Cancer Center - Commack
Commack, New York, 11725
Decatur Memorial Hospital - Illinois
Decatur, Illinois, 62526
Northwestern Medicine Cancer Center - Kishwaukee / Kishwaukee Cancer Center
DeKalb, Illinois, 60115
Henry Ford Health System
Detroit, Michigan, 48202
Duke University Medical Center
Durham, North Carolina, 27710
Southcoast Centers for Cancer Care - Fairhaven Site
Fairhaven, Massachusetts, 02719
Highlands Oncology Group
Fayetteville, Arkansas, 72703
Holy Cross Hospital - Michael and Dianne Bienes Comprehensive Cancer Center
Fort Lauderdale, Florida, 33308
Texas Oncology - Fort Worth Cancer Center
Fort Worth, Texas, 76104
Northwestern Medicine Cancer Center Delnor
Geneva, Illinois, 60134
Banner MD Anderson Cancer Center
Gilbert, Arizona, 85234
Vidant Medical Center
Greenville, North Carolina, 27834
Saint Francis Hospital Cancer Center
Greenville, South Carolina, 29607
Hackensack University Medical Center
Hackensack, New Jersey, 07601
Memorial Sloan Kettering Cancer Center - Westchester
Harrison, New York, 10604
Penn State Milton S. Hershey Medical Center
Hershey, Pennsylvania, 17033
University of Mississippi Medical Center
Jackson, Mississippi, 39213
Mayo Clinic Florida
Jacksonville, Florida, 32224
UC San Diego / Moores Cancer Center
La Jolla, California, 92093
Northwell Cancer Center / Monter Cancer Center
Lake Success, New York, 11042
McLaren Greater Lansing Hospital
Lansing, Michigan, 48910
OptumCare Cancer Center
Las Vegas, Nevada, 89102
Nebraska Hematology Oncology P.C.
Lincoln, Nebraska, 68506
Cardinal Bernardin Cancer Center / Loyola University Medical Center
Maywood, Illinois, 60153
University of Miami
Miami, Florida, 33136
Memorial Sloan Kettering Cancer Center - Monmouth
Middletown, New Jersey, 07748
Medical College of Wisconsin (Milwaukee)
Milwaukee, Wisconsin, 53226
NYU Winthrop Hospital
Mineola, New York, 11501
University of Minnesota
Minneapolis, Minnesota, 55455
Memorial Sloan Kettering Cancer Center - Bergen
Montvale, New Jersey, 07645
Carolina Urologic Research Center
Myrtle Beach, South Carolina, 29572
Tennessee Oncology / Sarah Cannon Research Institute
Nashville, Tennessee, 37203
Yale Cancer Center
New Haven, Connecticut, 06520
Tulane University Hospital and Clinic
New Orleans, Louisiana, 70112
Ochsner Clinic Foundation
New Orleans, Louisiana, 70121
New York University (NYU) Cancer Institute
New York, New York, 10016
Weill Cornell Medical College
New York, New York, 10065
Memorial Sloan Kettering Cancer Center
New York, New York, 10087-9049
Virginia Oncology Associates - Norfolk
Norfolk, Virginia, 23502
Eastern CT Hematology and Oncology Associates
Norwich, Connecticut, 06360
University of California Irvine - Newport
Orange, California, 92868
Fox Chase Cancer Center
Philadelphia, Pennsylvania, 19111
Mayo Clinic Arizona
Phoenix, Arizona, 85054
Allegheny General Hospital
Pittsburgh, Pennsylvania, 15212
University of Rochester Medical Center
Rochester, New York, 14642
University of California, Davis Comprehensive Cancer Center
Sacramento, California, 95817
Utah Cancer Specialists
Salt Lake City, Utah, 84106
University of Texas Health Science Center at San Antonio
San Antonio, Texas, 78229
University of California at San Francisco
San Francisco, California, 94134
Saint Joseph Heritage Medical Group
Santa Rosa, California, 95403
Maryland Oncology Hematology, P.A.
Silver Spring, Maryland, 20904
Medical Oncology Associates
Spokane, Washington, 99208
Washington University School of Medicine - Siteman Cancer Center
St Louis, Missouri, 63110
Stanford Cancer Center / Blood & Marrow Transplant Program
Stanford, California, 94305
Toledo Clinic Cancer Center
Toledo, Ohio, 43623
Arizona Oncology Associates, PC - HOPE
Tucson, Arizona, 85710
Texas Oncology - Tyler
Tyler, Texas, 75702
Memorial Sloan Kettering Cancer Center - Nassau
Uniondale, New York, 11553
Northwestern Medicine Cancer Center - Warrenville / Central DuPage Hospital - Cancer Care
Warrenville, Illinois, 60555
Georgetown University Medical Center
Washington D.C., District of Columbia, 20007
University of Kansas Cancer Center
Westwood, Kansas, 66205
Kaiser Permanente Southern California
Woodland Hills, California, 91367
France8 sites
Site FR33008
Bordeaux, 33000
Site FR33005
Dijon, 21000
Site FR33003
Lyon, 69008
Site FR33004
Marseille, 13273
Site FR33010
Moselle, 54519
Site FR33002
Nice, 06189
Site FR33006
Pierre-Bénite, 69310
Site FR33001
Strasbourg, 67200
Spain7 sites
Site ES34006
Barcelona, 08041
Site ES34008
Madrid, 28033
Site ES34001
Madrid, 28034
Site ES34012
Madrid, 28041
Site ES34007
Pamplona, 31008
Site ES34005
Sabadell, 08208
Site ES34004
Santander, 39008
Canada6 sites
Site CA11008
East Brampton, Ontario, L6R 3J7
Site CA11011
Kingston, Ontario, K7L 2V7
Site CA11005
Montreal, Quebec, H3T1E2
Site CA11013
Montreal, Quebec, H4A3J1
Site CA11002
Sherbrooke, Quebec, J1H 5N4
Site CA11001
Toronto, Ontario, M5G 2M9
About this study
Official title: A Study of Enfortumab Vedotin (ASG-22CE) as Monotherapy or in Combination With Other Anticancer Therapies for the Treatment of Urothelial Cancer
This study will test an experimental drug (enfortumab vedotin) alone and with different combinations of anticancer therapies. Pembrolizumab is an immune checkpoint inhibitor (CPI) that is used to treat patients with cancer of the urinary system (urothelial cancer). This type of cancer includes cancer of the bladder, renal pelvis, ureter or urethra. Some parts of the study will look at locally advanced or metastatic urothelial cancer (la/mUC), which means the cancer has spread to nearby tissues or to other areas of the body. Other parts of the study will look at muscle-invasive bladder cancer (MIBC), which is cancer at an earlier stage that has spread into the muscle wall of the bladder. This study will look at the side effects of enfortumab vedotin alone and with other anticancer therapies. A side effect is a response to a drug that is not part of the treatment effect. This study will also test if the cancer shrinks with the different treatment combinations.
Read the detailed description
This study will examine the safety and anticancer activity of enfortumab vedotin (EV) given intravenously as monotherapy and in combination with other anticancer therapies as first line (1L) and second line (2L) treatment for patients with urothelial cancer. The primary goal of the study is to determine the safety, tolerability, and efficacy of enfortumab vedotin alone and in combination with pembrolizumab and/or chemotherapy. The study will be conducted in multiple parts:
Locally advanced or metastatic urothelial cancer:
- Dose escalation
- Expansion
- Part 1: Cohorts A and Optional B
- Part 2: Cohorts D, E, and Optional F
- Part 3: Cohort G.
- Randomized Cohort K
- EV Monotherapy Arm
- EV Combination Arm
Muscle invasive bladder cancer:
- Cohort H
- Optional Cohort J
- Cohort L
- Conditions
- Carcinoma, Transitional Cell, Urinary Bladder Neoplasms, Urologic Neoplasms, Renal Pelvis Neoplasms, Urothelial Cancer, Ureteral Neoplasms
- Being tested
- enfortumab vedotin (EV), pembrolizumab, cisplatin, carboplatin, gemcitabine
- Keywords
- ASG-22ME, ASG-22CE, Antibody-drug conjugate, Antineoplastic agents, CPI, Enfortumab vedotin, MIBC, Locally advanced urothelial cancer, Cisplatin, Drug therapy, Carboplatin, Metastatic urothelial cancer, Nectin-4, Gemcitabine, Muscle invasive bladder cancer, Checkpoint Inhibitors, Pembrolizumab, PD-1 inhibitor
- Medical subject headings
- Carcinoma, Transitional Cell, Urinary Bladder Neoplasms, Urologic Neoplasms, Ureteral Neoplasms, Urethral Neoplasms
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
enfortumab vedotin (EV)Drug
Also called ASG-22CE, ASG-22ME, PADCEV
Intravenous (IV) infusion on days 1 and 8 every 21 days
pembrolizumabDrug
Also called Keytruda
IV infusion on day 1 every 21 days
cisplatinDrug
IV infusion on day 1 every 21 days
carboplatinDrug
IV infusion on day 1 every 21 days
gemcitabineDrug
IV infusion on days 1 and 8 every 21 days
| Study group | Role | What they receive |
|---|---|---|
| EV + Pembrolizumab in cisplatin-ineligible 1L and in 2L | Experimental | Dose Escalation: Enfortumab vedotin on days 1 and 8 plus pembrolizumab on day 1 every 21 days Receives: Drug: enfortumab vedotin (EV); Drug: pembrolizumab |
| Cohort A: EV + Pembrolizumab in cisplatin-ineligible 1L | Experimental | Enfortumab vedotin on days 1 and 8 plus pembrolizumab on day 1 every 21 days Receives: Drug: enfortumab vedotin (EV); Drug: pembrolizumab |
| Optional Cohort B: Enfortumab Vedotin + Pembrolizumab in 2L | Experimental | Enfortumab vedotin on days 1 and 8 plus pembrolizumab on day 1 every 21 days Receives: Drug: enfortumab vedotin (EV); Drug: pembrolizumab |
| Cohort D: Enfortumab Vedotin + Cisplatin in 1L | Experimental | Enfortumab vedotin on days 1 and 8 plus cisplatin on day 1 every 21 days Receives: Drug: enfortumab vedotin (EV); Drug: cisplatin |
| Cohort E: Enfortumab Vedotin + Carboplatin in 1L | Experimental | Enfortumab vedotin on days 1 and 8 plus carboplatin on day 1 every 21 days Receives: Drug: enfortumab vedotin (EV); Drug: carboplatin |
| Optional Cohort F: Enfortumab Vedotin+Gemcitabine in 1L and 2L | Experimental | Enfortumab vedotin and gemcitabine on days 1 and 8 every 21 days Receives: Drug: enfortumab vedotin (EV); Drug: gemcitabine |
| Cohort G: Enfortumab Vedotin + Platinum + Pembrolizumab in 1L | Experimental | Enfortumab vedotin on days 1 and 8 plus cisplatin or carboplatin on day 1 plus pembrolizumab on day 1 every 21 days Receives: Drug: enfortumab vedotin (EV); Drug: pembrolizumab; Drug: cisplatin; Drug: carboplatin |
| Cohort H: Enfortumab vedotin in MIBC neoadjuvant setting | Experimental | Enfortumab vedotin on days 1 and 8 every 21 days Receives: Drug: enfortumab vedotin (EV) |
| Optional Cohort J:EV+Pembrolizumab in MIBC neoadjuvant setting | Experimental | Enfortumab vedotin on days 1 and 8 plus pembrolizumab on day 1 every 21 days Receives: Drug: enfortumab vedotin (EV); Drug: pembrolizumab |
| Randomized Cohort K: Enfortumab Vedotin Monotherapy | Experimental | Enfortumab vedotin on days 1 and 8 every 21 days Receives: Drug: enfortumab vedotin (EV) |
| Randomized Cohort K: Enfortumab Vedotin + Pembrolizumab | Experimental | Enfortumab vedotin on days 1 and 8 plus pembrolizumab on day 1 every 21 days Receives: Drug: enfortumab vedotin (EV); Drug: pembrolizumab |
| Cohort L: Enfortumab vedotin in MIBC in perioperative setting | Experimental | Enfortumab vedotin on days 1 and 8 and every 21 days Receives: Drug: enfortumab vedotin (EV) |
What is being measured
The primary outcome is the main question the study is designed to answer.
Type, incidence, severity, seriousness, and relatedness of adverse events (Dose escalation and Expansion Parts 1 to 3 cohorts only)
Descriptive statistics will be used to summarize results.
Measured: Through 1 month following last dose, or end-of-treatment visit whichever is later, approximately 3 years anticipated.
Type, incidence, and severity of laboratory abnormalities (Dose escalation and Expansion Parts 1 to 3 cohorts only)
Descriptive statistics will be used to summarize results.
Measured: Through 1 month following last dose, or end-of-treatment visit whichever is later, approximately 3 years anticipated.
Confirmed objective response rate (ORR) per Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST 1.1) by blinded independent central review (BICR) (Cohort K only)
The proportion of patients with confirmed complete response (CR) or partial response (PR) according to RECIST 1.1
Measured: Up to 3 years
Pathological complete response (pCR) rate per central pathology review (MIBC cohorts only)
The proportion of patients with absence of viable tumor tissue at the time of radical cystectomy.
Measured: Up to approximately 5 months
Secondary outcomes (32)
Incidence of dose-limiting toxicity (DLT)
Incidence of DLTs (dose-escalation expansion Cohorts D, E, F, and the first 6 patients of Cohort G).
Measured: 21 days
Confirmed ORR by investigator assessment according to RECIST 1.1 (la/mUC cohorts only)
The proportion of patients with confirmed CR or PR according to RECIST 1.1.
Measured: Up to 3 years
Confirmed ORR by BICR according to RECIST 1.1 (Dose escalation and Cohort A only)
The proportion of patients with confirmed CR or PR according to RECIST 1.1
Measured: Up to 3 years
Confirmed ORR by investigator assessment per the modified RECIST 1.1 for immune-based therapeutics (iRECIST) (Dose escalation and Part 1-3 cohorts with pembrolizumab only)
The proportion of patients with confirmed CR or PR according to iRECIST.
Measured: Up to 3 years
Disease control rate (DCR) by investigator assessment according to RECIST 1.1 (la/mUC cohorts only)
Proportion of patients with CR, PR, or stable disease (SD) according to RECIST 1.1.
Measured: Up to 5 years
DCR by BICR according to RECIST 1.1 (Dose escalation, Cohort A, and randomized Cohort K only)
Proportion of patients with CR, PR, or stable disease (SD) according to RECIST 1.1
Measured: Up to 3 years
DCR by investigator assessment according to iRECIST (Dose escalation and Part 1-3 cohorts using pembrolizumab only)
Proportion of patients with CR, PR, or SD according to iRECIST.
Measured: Up to 3 years
Duration of response (DOR) by investigator assessment according to RECIST 1.1 (la/mUC cohorts only)
The time from first documentation of objective response (CR or PR that is subsequently confirmed) to the first documentation of progressive disease (PD per RECIST 1.1) or to death due to any cause, whichever comes first.
Measured: Up to 5 years
DOR by BICR according to RECIST 1.1 (Dose escalation, Cohort A, and randomized Cohort K only)
The time from first documentation of objective response (CR or PR that is subsequently confirmed) to the first documentation of PD per RECIST 1.1 or to death due to any cause, whichever comes first
Measured: Up to 5 years
DOR by investigator assessment according to iRECIST (Dose escalation and Part 1-3 cohorts with pembrolizumab only)
The time from first documentation of objective response (CR or PR that is subsequently confirmed) to the first documentation of PD per iRECIST or to death due to any cause, whichever comes first.
Measured: Up to 5 years
Progression free survival on study therapy (PFS) by investigator assessment according to RECIST 1.1 (la/mUC cohorts only)
The time from start of study treatment to first documentation of objective tumor progression (PD per RECIST 1.1) on or following study therapy, or to death due to any cause, whichever comes first.
Measured: Up to 5 years
PFS by BICR according to RECIST 1.1 (Dose escalation, Cohort A, and randomized Cohort K only)
The time from start of study treatment to first documentation of objective tumor progression (PD per RECIST 1.1) on or following study therapy, or to death due to any cause, whichever comes first
Measured: Up to 5 years
PFS by investigator assessment according to iRECIST (Dose escalation and Part 1-3 cohorts with pembrolizumab only)
The time from start of study treatment to first documentation of objective tumor progression (PD per iRECIST) on or following study therapy, or to death due to any cause, whichever comes first.
Measured: Up to 5 years
Event-free (EFS) on study therapy by BICR (Cohort L only)
The time from the start of study treatment to the first occurrence of any of the following events: (1) Radiographic disease progression precluding a curative intent surgery as assessed by BICR prior to RC+PLND. (2) Failure to undergo RC+PLND for participants with residual muscle-invasive disease and/or any radiographic disease present. (3) Gross residual disease left behind at time of RC+PLND. (4) Local or distant recurrence post-RC as assessed by CT or MRI and/or biopsy. (5) Death from any cause.
Measured: Up to 3 years
Event-free (EFS) on study therapy by investigator assessment (MIBC cohorts only)
The time from the start of study treatment to the first occurrence of any of the following events: (1) Radiographic disease progression precluding a curative intent surgery as assessed by BICR prior to RC+PLND. (2) Failure to undergo RC+PLND for participants with residual muscle-invasive disease and/or any radiographic disease present. (3) Gross residual disease left behind at time of RC+PLND. (4) Local or distant recurrence post-RC as assessed by CT or MRI and/or biopsy. (5) Death from any cause.
Measured: Up to 3 years
Overall survival (OS) (all cohorts)
The time from start of study treatment to date of death due to any cause.
Measured: Up to 5 years
Pharmacokinetics (PK) parameter for enfortumab vedotin: Maximum concentration (Cmax) (Dose escalation and Expansion Parts 1 to 3; non-randomized la/mUC cohorts only)
Cmax will be derived from the PK blood samples collected.
Measured: Through 2 cycles of treatment, up to 42 days
PK parameter for monomethyl auristatin E (MMAE): Cmax (Dose escalation and Expansion Parts 1 to 3; non-randomized la/mUC cohorts only)
Cmax will be derived from the PK blood samples collected.
Measured: Through 2 cycles of treatment, up to 42 days
PK parameter for total antibody (Tab): Cmax (Dose escalation and Expansion Parts 1 to 3; non-randomized la/mUC cohorts only)
Cmax will be derived from the PK blood samples collected.
Measured: Through 2 cycles of treatment, up to 42 days
Incidence of antitherapeutic antibodies (ATA) to enfortumab vedotin (Dose escalation and Expansion Parts 1 to 3; non-randomized la/mUC cohorts only)
Blood samples for ATA analysis will be collected.
Measured: Through 1 month following last dose, or end-of-treatment visit whichever is later, approximately 3 years anticipated.
PK parameter for enfortumab vedotin: Time to maximum concentration (Tmax) (Dose escalation and Expansion Parts 1 to 3; non-randomized la/mUC cohorts only)
Tmax will be derived from the PK blood samples collected.
Measured: Through 2 cycles of treatment, up to 42 days
PK parameter for MMAE: Tmax (Dose escalation and Expansion Parts 1 to 3; non-randomized la/mUC cohorts only)
Tmax will be derived from the PK blood samples collected.
Measured: Through 2 cycles of treatment, up to 42 days
PK parameter for Tab: Tmax (Dose escalation and Expansion Parts 1 to 3; non-randomized la/mUC cohorts only)
Tmax will be derived from the PK blood samples collected.
Measured: Through 2 cycles of treatment, up to 42 days
PK parameter for enfortumab vedotin: Area under the concentration-time curve (AUC) (Dose escalation and Expansion Parts 1 to 3; non-randomized la/mUC cohorts only)
AUC will be derived from the PK blood samples collected.
Measured: Through 2 cycles of treatment, up to 42 days
PK parameter for MMAE: AUC (Dose escalation and Expansion Parts 1 to 3; non-randomized la/mUC cohorts only)
AUC will be derived from the PK blood samples collected.
Measured: Through 2 cycles of treatment, up to 42 days
PK parameter for Tab: AUC (Dose escalation and Expansion Parts 1 to 3; non-randomized la/mUC cohorts only)
AUC will be derived from the PK blood samples collected.
Measured: Through 2 cycles of treatment, up to 42 days
Pathologic downstaging (pDS) rate by central pathology review (MIBC cohorts only)
The pDS rate is defined as patients with tumors <pT2 and N0 in examined tissue from radical cystectomy (RC) and pelvic lymph node dissection (PLND).
Measured: Up to approximately 5 months
Disease-free survival (DFS) by investigator assessment (MIBC cohorts only)
DFS is defined as the time from RC to the time of first occurrence of a DFS event, including local recurrence of urothelial cancer (UC), urinary tract recurrence of UC, distant metastasis of UC, or death from any cause.
Measured: Up to approximately 5 years
DFS by BICR (Cohort L only)
DFS is defined as the time from RC to the time of first occurrence of a DFS event
Measured: Up to 3 years
Type, incidence, severity, seriousness, and relatedness of AEs (Randomized Cohort K and MIBC cohorts only)
Descriptive statistics will be used to summarize results.
Measured: Through 1 month following last dose, or end-of-treatment visit whichever is later, up to approximately 3 years
Type, incidence, and severity of laboratory abnormalities (Randomized Cohort K and MIBC cohorts only)
Descriptive statistics will be used to summarize results.
Measured: Through 1 month following last dose, or end-of-treatment visit whichever is later, up to approximately 3 years
Percentage of planned radical cystectomy and pelvic lymph node dissections (RC+PLND) delayed due to treatment-related AEs (MIBC cohorts only)
Delayed is defined as greater than 12 weeks after the last dose of treatment.
Measured: Up to approximately 5 months
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted20 Sep 2017
- Study start11 Oct 2017
- Primary completion20 Feb 2026
- Study completion20 Feb 2026
Why it stopped: Sponsor stopped the study after meeting enrollment targets and primary objectives, and after collecting sufficient data for planned regulatory filings. The decision was not due to safety concerns, futility, or any regulatory request.
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (3)Papers the sponsor has linked to this study.
- Other trials for Carcinoma, Transitional CellStudies of the same condition, open and under way.
- More trials run by Astellas Pharma Global Development, Inc.The sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 1/2
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Sequential
- Model description
- multi-cohort, open-label, multicenter study, global
- Masking
- None (open label)
- Enrolment
- 348 participants (actual)
Sponsor and investigators
- Lead sponsor
- Astellas Pharma Global Development, Inc.
- Sponsor type
- Industry (pharma, biotech, devices)
- Collaborators
- Merck Sharp & Dohme LLC, Seagen Inc.
- Responsible party
- Sponsor
- Investigators
- Changting Meng, MD, Study director, Seagen Inc.Jason Lukas, MD, PhD, Study director, Seagen Inc.
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT03288545
- Sponsor's protocol ID
- SGN22E-002
- Other IDs
- MK-3475-869, KEYNOTE KN-869
- Acronym
- EV-103
- Status last verified
- Mar 2026
- First submitted
- 18 Sep 2017
- Last updated
- 24 Mar 2026
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- Yes
- FDA-regulated device
- No
- Individual data sharing
- Undecided
- Expanded access
- Available
Publications
Milowsky MI, O'Donnell PH, Hoimes CJ, Petrylak DP, Flaig TW, Moon HH, Friedlander TW, Mar N, McKay RR, Srinivas S, Gravis G, Ramamurthy C, Bupathi M, Bracarda S, Wright P, Hepp Z, Carret AS, Yu Y, Dillon R, Kataria R, Beaumont JL, Purnajo I, Rosenberg JE. Patient-Reported Outcomes in Patients With Advanced Urothelial Cancer Who Are Ineligible for Cisplatin and Treated With First-Line Enfortumab Vedotin Alone or With Pembrolizumab. J Clin Oncol. 2024 Apr 20;42(12):1403-1414. doi: 10.1200/JCO.23.01547. Epub 2024 Jan 12.
PubMed 38215355O'Donnell PH, Milowsky MI, Petrylak DP, Hoimes CJ, Flaig TW, Mar N, Moon HH, Friedlander TW, McKay RR, Bilen MA, Srinivas S, Burgess EF, Ramamurthy C, George S, Geynisman DM, Bracarda S, Borchiellini D, Geoffrois L, Maroto Rey JP, Ferrario C, Carret AS, Yu Y, Guseva M, Homet Moreno B, Rosenberg JE. Enfortumab Vedotin With or Without Pembrolizumab in Cisplatin-Ineligible Patients With Previously Untreated Locally Advanced or Metastatic Urothelial Cancer. J Clin Oncol. 2023 Sep 1;41(25):4107-4117. doi: 10.1200/JCO.22.02887. Epub 2023 Jun 27.
PubMed 37369081Hoimes CJ, Flaig TW, Milowsky MI, Friedlander TW, Bilen MA, Gupta S, Srinivas S, Merchan JR, McKay RR, Petrylak DP, Sasse C, Moreno BH, Yu Y, Carret AS, Rosenberg JE. Enfortumab Vedotin Plus Pembrolizumab in Previously Untreated Advanced Urothelial Cancer. J Clin Oncol. 2023 Jan 1;41(1):22-31. doi: 10.1200/JCO.22.01643. Epub 2022 Aug 30.
PubMed 36041086
Study at a glance
From the registry record, last updated by the sponsor on 24 Mar 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Study of Enfortumab Vedotin (ASG-22CE) as Monotherapy or in Combination With Other Anticancer Therapies for the Treatment of Urothelial Cancer
- ClinicalTrials.gov ID
- NCT03288545
- Acronym / sponsor ID
- EV-103 / SGN22E-002
- Conditions
- Carcinoma, Transitional Cell, Urinary Bladder Neoplasms, Urologic Neoplasms, Renal Pelvis Neoplasms, Urothelial Cancer, Ureteral Neoplasms
- Keywords
- ASG-22ME, ASG-22CE, Antibody-drug conjugate, Antineoplastic agents, CPI, Enfortumab vedotin, MIBC, Locally advanced urothelial cancer
- Phase
- Phase 1/2
- Study type
- Interventional
- Recruitment status
- TerminatedReason stopped: Sponsor stopped the study after meeting enrollment targets and primary objectives, and after collecting sufficient data for planned regulatory filings. The decision was not due to safety concerns, futility, or any regulatory request.
- Enrolment
- 348 participants (actual)
- Lead sponsor
- Astellas Pharma Global Development, Inc.Industry (pharma, biotech, devices)
- Collaborators
- Merck Sharp & Dohme LLC, Seagen Inc.
- Study start
- 11 Oct 2017 (actual)
- Primary completion
- 20 Feb 2026 (actual)
- Study completion
- 20 Feb 2026 (actual)
- First posted
- 20 Sep 2017 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This study will test an experimental drug (enfortumab vedotin) alone and with different combinations of anticancer therapies. Pembrolizumab is an immune checkpoint inhibitor (CPI) that is used to treat patients with cancer of the urinary system (urothelial cancer). This type of cancer includes cancer of the bladder, renal pelvis, ureter or urethra. Some parts of the study will look at locally advanced or metastatic urothelial cancer (la/mUC), which means the cancer has spread to nearby tissues or to other areas of the body. Other parts of the study will look at muscle-invasive bladder cancer (MIBC), which is cancer at an earlier stage that has spread into the muscle wall of the bladder. This study will look at the side effects of enfortumab vedotin alone and with other anticancer therapies. A side effect is a response to a drug that is not part of the treatment effect. This study will also test if the cancer shrinks with the different treatment combinations.
Detailed description
This study will examine the safety and anticancer activity of enfortumab vedotin (EV) given intravenously as monotherapy and in combination with other anticancer therapies as first line (1L) and second line (2L) treatment for patients with urothelial cancer. The primary goal of the study is to determine the safety, tolerability, and efficacy of enfortumab vedotin alone and in combination with pembrolizumab and/or chemotherapy. The study will be conducted in multiple parts:
Locally advanced or metastatic urothelial cancer:
- Dose escalation
- Expansion
- Part 1: Cohorts A and Optional B
- Part 2: Cohorts D, E, and Optional F
- Part 3: Cohort G.
- Randomized Cohort K
- EV Monotherapy Arm
- EV Combination Arm
Muscle invasive bladder cancer:
- Cohort H
- Optional Cohort J
- Cohort L
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Sequential
- Masking
- None (open label)
- Number of arms
- 12
- Model description
- multi-cohort, open-label, multicenter study, global
| Arm | Type | Receives |
|---|---|---|
| EV + Pembrolizumab in cisplatin-ineligible 1L and in 2L | Experimental | Drug: enfortumab vedotin (EV), Drug: pembrolizumabDose Escalation: Enfortumab vedotin on days 1 and 8 plus pembrolizumab on day 1 every 21 days |
| Cohort A: EV + Pembrolizumab in cisplatin-ineligible 1L | Experimental | Drug: enfortumab vedotin (EV), Drug: pembrolizumabEnfortumab vedotin on days 1 and 8 plus pembrolizumab on day 1 every 21 days |
| Optional Cohort B: Enfortumab Vedotin + Pembrolizumab in 2L | Experimental | Drug: enfortumab vedotin (EV), Drug: pembrolizumabEnfortumab vedotin on days 1 and 8 plus pembrolizumab on day 1 every 21 days |
| Cohort D: Enfortumab Vedotin + Cisplatin in 1L | Experimental | Drug: enfortumab vedotin (EV), Drug: cisplatinEnfortumab vedotin on days 1 and 8 plus cisplatin on day 1 every 21 days |
| Cohort E: Enfortumab Vedotin + Carboplatin in 1L | Experimental | Drug: enfortumab vedotin (EV), Drug: carboplatinEnfortumab vedotin on days 1 and 8 plus carboplatin on day 1 every 21 days |
| Optional Cohort F: Enfortumab Vedotin+Gemcitabine in 1L and 2L | Experimental | Drug: enfortumab vedotin (EV), Drug: gemcitabineEnfortumab vedotin and gemcitabine on days 1 and 8 every 21 days |
| Cohort G: Enfortumab Vedotin + Platinum + Pembrolizumab in 1L | Experimental | Drug: enfortumab vedotin (EV), Drug: pembrolizumab, Drug: cisplatin, Drug: carboplatinEnfortumab vedotin on days 1 and 8 plus cisplatin or carboplatin on day 1 plus pembrolizumab on day 1 every 21 days |
| Cohort H: Enfortumab vedotin in MIBC neoadjuvant setting | Experimental | Drug: enfortumab vedotin (EV)Enfortumab vedotin on days 1 and 8 every 21 days |
| Optional Cohort J:EV+Pembrolizumab in MIBC neoadjuvant setting | Experimental | Drug: enfortumab vedotin (EV), Drug: pembrolizumabEnfortumab vedotin on days 1 and 8 plus pembrolizumab on day 1 every 21 days |
| Randomized Cohort K: Enfortumab Vedotin Monotherapy | Experimental | Drug: enfortumab vedotin (EV)Enfortumab vedotin on days 1 and 8 every 21 days |
| Randomized Cohort K: Enfortumab Vedotin + Pembrolizumab | Experimental | Drug: enfortumab vedotin (EV), Drug: pembrolizumabEnfortumab vedotin on days 1 and 8 plus pembrolizumab on day 1 every 21 days |
| Cohort L: Enfortumab vedotin in MIBC in perioperative setting | Experimental | Drug: enfortumab vedotin (EV)Enfortumab vedotin on days 1 and 8 and every 21 days |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (20 listed)
- Locally advanced or metastatic urothelial cancer (la/mUC) - Cohorts A, B, D, E, F, G and K.
- Muscle Invasive Bladder Cancer (MIBC)- Cohorts H, J and L.
Key exclusion criteria (19 listed)
- la/mUC - Cohorts A, B, D, E, F, G, and K
- MIBC - Cohorts H, J, and L
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| enfortumab vedotin (EV)Also: ASG-22CE, ASG-22ME, PADCEVIntravenous (IV) infusion on days 1 and 8 every 21 days | Drug | Cohort A: EV + Pembrolizumab in cisplatin-ineligible 1L, Cohort D: Enfortumab Vedotin + Cisplatin in 1L, Cohort E: Enfortumab Vedotin + Carboplatin in 1L, Cohort G: Enfortumab Vedotin + Platinum + Pembrolizumab in 1L, Cohort H: Enfortumab vedotin in MIBC neoadjuvant setting, Cohort L: Enfortumab vedotin in MIBC in perioperative setting, EV + Pembrolizumab in cisplatin-ineligible 1L and in 2L, Optional Cohort B: Enfortumab Vedotin + Pembrolizumab in 2L, Optional Cohort F: Enfortumab Vedotin+Gemcitabine in 1L and 2L, Optional Cohort J:EV+Pembrolizumab in MIBC neoadjuvant setting, Randomized Cohort K: Enfortumab Vedotin + Pembrolizumab, Randomized Cohort K: Enfortumab Vedotin Monotherapy |
| pembrolizumabAlso: KeytrudaIV infusion on day 1 every 21 days | Drug | Cohort A: EV + Pembrolizumab in cisplatin-ineligible 1L, Cohort G: Enfortumab Vedotin + Platinum + Pembrolizumab in 1L, EV + Pembrolizumab in cisplatin-ineligible 1L and in 2L, Optional Cohort B: Enfortumab Vedotin + Pembrolizumab in 2L, Optional Cohort J:EV+Pembrolizumab in MIBC neoadjuvant setting, Randomized Cohort K: Enfortumab Vedotin + Pembrolizumab |
| cisplatinIV infusion on day 1 every 21 days | Drug | Cohort D: Enfortumab Vedotin + Cisplatin in 1L, Cohort G: Enfortumab Vedotin + Platinum + Pembrolizumab in 1L |
| carboplatinIV infusion on day 1 every 21 days | Drug | Cohort E: Enfortumab Vedotin + Carboplatin in 1L, Cohort G: Enfortumab Vedotin + Platinum + Pembrolizumab in 1L |
| gemcitabineIV infusion on days 1 and 8 every 21 days | Drug | Optional Cohort F: Enfortumab Vedotin+Gemcitabine in 1L and 2L |
Primary outcome
Type, incidence, severity, seriousness, and relatedness of adverse events (Dose escalation and Expansion Parts 1 to 3 cohorts only)
Time frame: Through 1 month following last dose, or end-of-treatment visit whichever is later, approximately 3 years anticipated.
Descriptive statistics will be used to summarize results.
Type, incidence, and severity of laboratory abnormalities (Dose escalation and Expansion Parts 1 to 3 cohorts only)
Time frame: Through 1 month following last dose, or end-of-treatment visit whichever is later, approximately 3 years anticipated.
Descriptive statistics will be used to summarize results.
Confirmed objective response rate (ORR) per Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST 1.1) by blinded independent central review (BICR) (Cohort K only)
Time frame: Up to 3 years
The proportion of patients with confirmed complete response (CR) or partial response (PR) according to RECIST 1.1
Pathological complete response (pCR) rate per central pathology review (MIBC cohorts only)
Time frame: Up to approximately 5 months
The proportion of patients with absence of viable tumor tissue at the time of radical cystectomy.
32 secondary outcomes
Incidence of dose-limiting toxicity (DLT)
Time frame: 21 days
Confirmed ORR by investigator assessment according to RECIST 1.1 (la/mUC cohorts only)
Time frame: Up to 3 years
Confirmed ORR by BICR according to RECIST 1.1 (Dose escalation and Cohort A only)
Time frame: Up to 3 years
Confirmed ORR by investigator assessment per the modified RECIST 1.1 for immune-based therapeutics (iRECIST) (Dose escalation and Part 1-3 cohorts with pembrolizumab only)
Time frame: Up to 3 years
Disease control rate (DCR) by investigator assessment according to RECIST 1.1 (la/mUC cohorts only)
Time frame: Up to 5 years
DCR by BICR according to RECIST 1.1 (Dose escalation, Cohort A, and randomized Cohort K only)
Time frame: Up to 3 years
DCR by investigator assessment according to iRECIST (Dose escalation and Part 1-3 cohorts using pembrolizumab only)
Time frame: Up to 3 years
Duration of response (DOR) by investigator assessment according to RECIST 1.1 (la/mUC cohorts only)
Time frame: Up to 5 years
DOR by BICR according to RECIST 1.1 (Dose escalation, Cohort A, and randomized Cohort K only)
Time frame: Up to 5 years
DOR by investigator assessment according to iRECIST (Dose escalation and Part 1-3 cohorts with pembrolizumab only)
Time frame: Up to 5 years
Progression free survival on study therapy (PFS) by investigator assessment according to RECIST 1.1 (la/mUC cohorts only)
Time frame: Up to 5 years
PFS by BICR according to RECIST 1.1 (Dose escalation, Cohort A, and randomized Cohort K only)
Time frame: Up to 5 years
PFS by investigator assessment according to iRECIST (Dose escalation and Part 1-3 cohorts with pembrolizumab only)
Time frame: Up to 5 years
Event-free (EFS) on study therapy by BICR (Cohort L only)
Time frame: Up to 3 years
Event-free (EFS) on study therapy by investigator assessment (MIBC cohorts only)
Time frame: Up to 3 years
Overall survival (OS) (all cohorts)
Time frame: Up to 5 years
Pharmacokinetics (PK) parameter for enfortumab vedotin: Maximum concentration (Cmax) (Dose escalation and Expansion Parts 1 to 3; non-randomized la/mUC cohorts only)
Time frame: Through 2 cycles of treatment, up to 42 days
PK parameter for monomethyl auristatin E (MMAE): Cmax (Dose escalation and Expansion Parts 1 to 3; non-randomized la/mUC cohorts only)
Time frame: Through 2 cycles of treatment, up to 42 days
PK parameter for total antibody (Tab): Cmax (Dose escalation and Expansion Parts 1 to 3; non-randomized la/mUC cohorts only)
Time frame: Through 2 cycles of treatment, up to 42 days
Incidence of antitherapeutic antibodies (ATA) to enfortumab vedotin (Dose escalation and Expansion Parts 1 to 3; non-randomized la/mUC cohorts only)
Time frame: Through 1 month following last dose, or end-of-treatment visit whichever is later, approximately 3 years anticipated.
PK parameter for enfortumab vedotin: Time to maximum concentration (Tmax) (Dose escalation and Expansion Parts 1 to 3; non-randomized la/mUC cohorts only)
Time frame: Through 2 cycles of treatment, up to 42 days
PK parameter for MMAE: Tmax (Dose escalation and Expansion Parts 1 to 3; non-randomized la/mUC cohorts only)
Time frame: Through 2 cycles of treatment, up to 42 days
PK parameter for Tab: Tmax (Dose escalation and Expansion Parts 1 to 3; non-randomized la/mUC cohorts only)
Time frame: Through 2 cycles of treatment, up to 42 days
PK parameter for enfortumab vedotin: Area under the concentration-time curve (AUC) (Dose escalation and Expansion Parts 1 to 3; non-randomized la/mUC cohorts only)
Time frame: Through 2 cycles of treatment, up to 42 days
PK parameter for MMAE: AUC (Dose escalation and Expansion Parts 1 to 3; non-randomized la/mUC cohorts only)
Time frame: Through 2 cycles of treatment, up to 42 days
PK parameter for Tab: AUC (Dose escalation and Expansion Parts 1 to 3; non-randomized la/mUC cohorts only)
Time frame: Through 2 cycles of treatment, up to 42 days
Pathologic downstaging (pDS) rate by central pathology review (MIBC cohorts only)
Time frame: Up to approximately 5 months
Disease-free survival (DFS) by investigator assessment (MIBC cohorts only)
Time frame: Up to approximately 5 years
DFS by BICR (Cohort L only)
Time frame: Up to 3 years
Type, incidence, severity, seriousness, and relatedness of AEs (Randomized Cohort K and MIBC cohorts only)
Time frame: Through 1 month following last dose, or end-of-treatment visit whichever is later, up to approximately 3 years
Type, incidence, and severity of laboratory abnormalities (Randomized Cohort K and MIBC cohorts only)
Time frame: Through 1 month following last dose, or end-of-treatment visit whichever is later, up to approximately 3 years
Percentage of planned radical cystectomy and pelvic lymph node dissections (RC+PLND) delayed due to treatment-related AEs (MIBC cohorts only)
Time frame: Up to approximately 5 months
Results and safety
The study was stopped early (reason given: Sponsor stopped the study after meeting enrollment targets and primary objectives, and after collecting sufficient data for planned regulatory filings. The decision was not due to safety concerns, futility, or any regulatory request.). Results are not available in the source record.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 24 Mar 2026.
- Derived from this study: PubMed 38215355Milowsky MI, O'Donnell PH, Hoimes CJ, Petrylak DP, Flaig TW, Moon HH, Friedlander TW, Mar N, McKay RR, Srinivas S, Gravis G, Ramamurthy C, Bupathi M, Bracarda S, Wright P, Hepp Z, Carret AS, Yu Y, Dillon R, Kataria R, Beaumont JL, Purnajo I, Rosenberg JE. Patient-Reported Outcomes in Patients With Advanced Urothelial Cancer Who Are Ineligible for Cisplatin and Treated With First-Line Enfortumab Vedotin Alone or With Pembrolizumab. J Clin Oncol. 2024 Apr 20;42(12):1403-1414. doi: 10.1200/JCO.23.01547. Epub 2024 Jan 12.
- Derived from this study: PubMed 37369081O'Donnell PH, Milowsky MI, Petrylak DP, Hoimes CJ, Flaig TW, Mar N, Moon HH, Friedlander TW, McKay RR, Bilen MA, Srinivas S, Burgess EF, Ramamurthy C, George S, Geynisman DM, Bracarda S, Borchiellini D, Geoffrois L, Maroto Rey JP, Ferrario C, Carret AS, Yu Y, Guseva M, Homet Moreno B, Rosenberg JE. Enfortumab Vedotin With or Without Pembrolizumab in Cisplatin-Ineligible Patients With Previously Untreated Locally Advanced or Metastatic Urothelial Cancer. J Clin Oncol. 2023 Sep 1;41(25):4107-4117. doi: 10.1200/JCO.22.02887. Epub 2023 Jun 27.
- Derived from this study: PubMed 36041086Hoimes CJ, Flaig TW, Milowsky MI, Friedlander TW, Bilen MA, Gupta S, Srinivas S, Merchan JR, McKay RR, Petrylak DP, Sasse C, Moreno BH, Yu Y, Carret AS, Rosenberg JE. Enfortumab Vedotin Plus Pembrolizumab in Previously Untreated Advanced Urothelial Cancer. J Clin Oncol. 2023 Jan 1;41(1):22-31. doi: 10.1200/JCO.22.01643. Epub 2022 Aug 30.
- Individual participant dataSharing planned: Undecided
Related trials for Carcinoma, Transitional Cell
RecruitingPhase 1/2
Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)
Solid Tumor, Non-Small Cell Lung Cancer
RecruitingPhase 2/3
Testing the Role of DNA Released From Tumor Cells Into the Blood in Guiding the Use of Immunotherapy After Surgical Removal of the Bladder, Kidney, Ureter, and Urethra for Urothelial Cancer Treatment, MODERN Study
Muscle Invasive Bladder Urothelial Carcinoma, Muscle Invasive Renal Pelvis Urothelial Carcinoma
Active, not recruitingPhase 1
Prospective Exploratory Study of FAPi PET/CT With Histopathology Validation in Patients With Various Cancers
Bladder Carcinoma, Cervical Carcinoma
RecruitingObservational study
Registry Platform Urologic Cancer
Renal Cell Carcinoma, Urothelial Carcinoma
RecruitingPhase 1
A Study to Learn About the Study Medicine Called PF-08046876 in People With Advanced Solid Tumors
Advanced/Metastatic Solid Tumors, Bladder Cancer
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Changting Meng, MD study director
Seagen Inc.
Jason Lukas, MD, PhD study director
Seagen Inc.
106 sites in 6 countries: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 1/2 study testing enfortumab vedotin (EV), pembrolizumab and cisplatin in people with Carcinoma, Transitional Cell and Urinary Bladder Neoplasms, run by Astellas Pharma Global Development, Inc. at 106 sites in 6 countries.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 20 inclusion and 19 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: stopped early, as of the sponsor's last update on 24 Mar 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 106 sites in United States, France, Spain, Canada, Italy and 1 more country. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this combined phase mean?
Phase 1 studies test a treatment in a small group of people for the first time or in a new way, mainly to check safety and find the right dose.
Phase 2 studies give the treatment to a larger group to see whether it has the intended effect and to keep checking safety.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
The study was stopped early (reason given: Sponsor stopped the study after meeting enrollment targets and primary objectives, and after collecting sufficient data for planned regulatory filings. The decision was not due to safety concerns, futility, or any regulatory request.). Results are not available in the source record.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Type, incidence, severity, seriousness, and relatedness of adverse events (Dose escalation and Expansion Parts 1 to 3 cohorts only) (time frame: Through 1 month following last dose, or end-of-treatment visit whichever is later, approximately 3 years anticipated.). The study lists 4 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT03288545, which also lists 3 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 24 Mar 2026.